Concepedia

Daratumumab, lenalidomide, and dexamethasone combination in relapsed/refractory myeloma patients: a real-life single-center experience

Elisabetta Antonioli, Michela Staderini, Sofia Pilerci, Federico Perfetto, Francesco Cappelli, Marco Allinovi, Chiara Nozzoli, Irene Attucci, Alessandra Buzzichelli, Maria Messeri,

Leukemia & lymphoma/Leukemia and lymphoma · 2020 · 13 citations · 11 references

DOI

Concepts

Abstract

daratumomab

References

11

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

Meletios Α. Dimopoulos, Albert Oriol, Hareth Nahi et al. · New England Journal of Medicine · 2016 · 1.4K citations · Full text

, , +16

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

Michel de Weers, Yu‐Tzu Tai, Michael S. van der Veer et al. · The Journal of Immunology · 2010 · 1K citations · Full text

, , +17

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

Sagar Lonial, Brendan M. Weiss, Saad Z. Usmani et al. · The Lancet · 2016 · 850 citations

, , +14

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

Marije B. Overdijk, Sandra Verploegen, Marijn Bögels et al. · mAbs · 2015 · 503 citations · Full text

, , +17

Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study

Nizar J. Bahlis, Meletios Α. Dimopoulos, Darrell White et al. · Leukemia · 2020 · 238 citations · Full text

, , +17